MPT — MEDICAL PPTYS TRUST INC
Public company
Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About MEDICAL PPTYS TRUST INC (MPT)
MEDICAL PPTYS TRUST INC (MPT) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Philippe Laffont (Coatue Management), valued at $23M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Tracked investors reporting MPT
- Philippe LaffontMar 31, 2026Coatue ManagementShares4.5MValue$21M% Portfolio0.07%
- Ken GriffinDec 31, 2025Citadel AdvisorsShares3.5MValue$17.4M% Portfolio0.01%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares96.8KValue$448K% Portfolio0.00%
Recent activity
- $22.6MMay 15, 2026
- $21MMay 15, 2026
- New$448KMay 15, 2026
Frequently asked questions
- How many institutional investors hold MPT?
- 3 tracked institutional investors disclosed a position in MPT (MEDICAL PPTYS TRUST INC) in their most recent 13F filing.
- Who is the largest institutional holder of MPT?
- Philippe Laffont, Coatue Management, holds the largest disclosed position in MPT, valued at $23M.
- Did institutional ownership of MPT increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited MPT.
- Where does this MPT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.